Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 1
1(33.3%)
Phase 2
1(33.3%)
3Total
N/A(1)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02344355Phase 2Active Not Recruiting

A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme

Role: lead

NCT04900792Phase 1Active Not Recruiting

A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma

Role: lead

NCT03658343Completed

T2* MRI Analysis for Sarcoma

Role: lead

NCT01975766Not ApplicableTerminated

Ketogenic Diet Phase 1 for Head & Neck Cancer

Role: lead

All 4 trials loaded